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Extended Abstract
Introduction: During evolution, the molecular messages such as
Wnt/b-catenin, Pin1/mutant p53, and Hedgehog compose of intracel-
lular signalling pathways. Mutations of these molecules may be car-
cinogenic or cause tumor progression. Among these, Wnt signaling
pathway plays an important role in evolution and cancer induction.
High Mobility Group A (HMGA) proteins are also chromatin
oncogenic factors that are involved in Wnt signaling and amplify
the effects of this signal. They may bind to AT-rich DNA sequences
in the minor groove.
Literature review: HMGs are a set of non-histone oncogenic pro-
teins that modify chromatin structure; this group of proteins is subdi-
vided into three families: HMGA (containing AT-hooks), HMGB
(containing HMG-boxes) and HMGN (containing nucleosomal bind-
ing domains). HMGAproteins are expressed in undifferentiated tissues
and a variety of tumors. These proteins include HMGA1 (HMGA1a,
HMGA1b and HMGA1c variants that derived from alternative splicing
of HMGA1 mRNA) and HMGA2 that encoded by two genes.
These proteins contain three DNA-binding domains with short
repeats, called AT-hook by the amino acid sequence K/RXRGRP(X
¼ glycine or proline), which binds to AT-rich DNA regions in theminor
groove and mediate accumulation of transcription factors and co-tran-
scription and formation of enhanceosome complex, and alter the
expression of target genes by modifying chromatin conformation in
the promoter or enhancers (Fig.1.B ) and has a tail at the end of C- ter-
minal involved in protein-protein interaction or gene transcription reg-
ulation. When these proteins bind to DNA molecule in specific
sequence, their AT-hook motifs change from a disordered to ordered
conformation and lead to structure alteration and DNA bending by dif-
ferentways including: bending, straightening, unwinding, and inducing
looping in linear DNA molecules. These proteins are also capable of
binding to the nucleosome structure in competition with histone H1.
Considering the importance of histone H1 in maintaining nucleo-
some structure, HMGA1 can bindto linker DNA of histone H1and
reduces the binding affinity of H1 for DNA through post-translational
modifications or phosphorylation of histone H1, undermining the
nucleosome structure.
These proteins play generally an important role in the reconstruc-
tion of stem cell, proliferation and differentiation. They also act as a
mediator in viral integration, modification of chromatin structure, neo-
plastic transformation, and metastatic progression. HMGA proteins
are overexpressed during embryonic development, while down regu-
lated in differentiated normal cells and matured tissues. They can be
induced by oncogenes Ras, C-myc, N-myc, transcription factors, epi-
dermal and fibroblastic growth factors and hypoxic conditions.
Studies on the activity of the HMGA1 group proteins showed that
these proteins through cooperation with the Wnt/beta-catenin, Pin1/
mutant p53 signaling pathways promote acquisition of stemness
and epithelial to mesenchymal transition (EMT) features during car-
cinogenesis. With activity of this signal, b-catenin translocates from
membrane adhesion junctions to the nucleus.
Also studies have shown that the removal b-catenin or its down-
stream C-myc reduce HMGA1 expression, which suggest thatHMGA1 locates in the downstream of Wnt signaling pathway.
Also, by reducing the expression of HMGA1, b-catenin returns again
to its position in the membrane and cellular junctions, and modulates
expression of the Wnt pathway intermediates.
Further investigations showed that the Wnt signaling pathway reg-
ulates positively HMGA1 gene through C-myc, as a result causes
continued proliferation of gastric cancer cells. In gastric cancer cells
depletion of HMGA1 reduces significantly the growth of these gastric
cancer cells. Furthermore HMGA2 by inhibiting the Axin expression
protects b-catenin from destruction. As a result HMGAs is induced
by oncogenic pathways and cause malignant phenotype. The expres-
sion of HMGA1 increases in a variety of human cancers, including
thyroid, prostate, colon and breast cancers.
Conclusion: Since gastric cancer is caused by environmental and
various oncogenic factors, analysis of molecules involved in develop-
ment and progression of this tumor can provide a clear vision for the
treatment of this deadly disease. The family of HMGA proteins have
a direct effect on cancer cells and due to their minimal presence in
differentiated cells, can act as a marker of tumor cells.
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Fig. 1. A) HMGA proteins displace histone H1 from the chromatin. HMGA
binding to linker DNA in the nucleosum and the subsequent displacement
of histone H1 leads to decompactness of the chromatin. B) HMGA1 binding
to enhancers or promoter causes accumulation of transcription factors, local-
ization of enhancers in the promoter adjacent and thus, increase gene expres-
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Extended Abstract
Introduction: Corresponding to the global status of cancer, the bur-
den of cancer is increasing in Iran in recent decades. Cancer is the third
leading cause of death in Iran after coronary heart disease and accidents.
Recent studies indicate an age adjusted incidence of 165 per 100,000
men and 141 per 100,000women of all kinds of cancer in the population
of Tehran. In terms of cancer risk and incidence, this population is a
fairly representative population of the whole country.
From 1996 to 2000, a retrospective survey was carried out to
ascertain the incidence of cancers in five provinces including Ardebil,
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south of Iran. These provinces covered about 16 percent of the pop-
ulation of Iran in 1996. Available medical records of cancer patients
in public/private hospitals and diagnostic/treatment facilities as well
as death certificates of these five provinces were collected. During
this period, there were 28,022 new cancer cases (57% men; 42%
women; 1% unknown sex). The mean age at diagnosis was 55
(median age 60). In terms of age-standardized rate (per 100,000),
the most common cancers in men were stomach (22.5), esophagus
(12.1), bladder (7.5), lung (6.5), colon/rectum (6.2) and prostate
(5.6). The leading female cancers were breast (13.3), stomach (9.3),
esophagus (8.9), colon/rectum (6.0), leukemia (2.4) and cervical can-
cer (2.3). It was predicted that the annual number of new cases in year
2010 in Iran was 53,000, which increased 65% compared to 1996
(95% in women; 46% in men). Generally, the incidence of cancer
in Iran was among the lowest in the world. It is expected that it
will rise dramatically in the future because of anticipated increase
in life expectancy and westernized lifestyle. This increase in the num-
ber of new cases is a huge burden for the health care system.
Without correction, cancer occurrence measures can be remark-
ably under-estimated. Therefore, measuring the actual incidence
rate of cancer requires the use of appropriate epidemiological meth-
ods. Fallah M. and Kharazmi E. used a novel method to compensate
under-ascertainment of cancer cases in the very elderly (aged >65) to
calculate corrected Iran cancer incidence. The crude rate was 13.6%
(men 18.7%; women 8.1%) under-estimated. The under-enumeration
was 18.9% for the age standardized rate (men 25.4%; women 11.8%).
There were about 7,000 new cancer cases more than original report
(by 58,000 new cancer cases) in 2002. Accordingly, corrected inci-
dence for the year 2050 will be 26.1% higher (men 32.8%;
women17.3%) than the original estimate (49,000 more).
Cancer registry status: Cancer registry is an important tool for
any successful cancer control program. Based on the report by Par-
kin et al (2002), there are only three countries around Iran including
Oman, Kuwait and Pakistan that have population-based cancer
registry. Compulsory report of cancer cases as a bill was passed
by Iranian Parliament in 1984. This was a good basic action that
led to microscopic verification of the majority of cancer cases in
Iran. Established cancer registries in Iran are including Mazan-
daran, Tehran, Shiraz, Ardabil and Iranian National Cancer Regis-
try. The registry strategy has undergone several modifications
over the past decades. The obligation to notify the cancer registries
of new cancer cases has been a legal requirement since 1994. While
only 18% of all estimated cancer cases were reported in the first
reports, this rate increased to 81% in 2005 following establishment
of cancer registries. But reporting to the Ministry of Health Registry
was far from complete.
Cancer research status: A network of cancer researchers was
established in 1998 in order to develop better means of communi-
cation, resource sharing and effective research management as
well as preventing inefficiency and wasting of resources available
to cancer researchers and scientists in Iran. A study was carried
out to draw a set of priority areas of cancer research in order to uti-
lize these priorities as broader policy for decision-making on a
comprehensive cancer control program at the national level in
Iran. The overall assessment of this study indicated the top first
five areas of research priorities on cancer including; 1) Cancer sur-
veillance and registration as the first priority; 2) Exogenous factors
related to the origin and cause of the cancer; 3) Surveillance -
patient care and survivorship issues; 4) Issues of patient qualityof life in end-of-life care; and 5) Cost analyses and health care
delivery of cancer services.
Cancer diagnosis: Although, cancer patients have access to the
expert professionals as well as sufficient cancer detection facilities
in Iran, the delay in diagnosis is still an important issue. The delay
time in diagnosing and treating different cancers in various studies
is about 2 to 5 months.
Delay in diagnosis affects the treatment and prognosis of cancer.
Studies showed that delays related to the patients were longer than
those related to the professionals. Patient delay makes a critical con-
tribution to late diagnosis and poor survival in cases of cancer.
Delayed presentation of asymptomatic cancer is a public health issue
in Iran, making a major contribution to low survival. Despite the
importance of this problem, current knowledge is insufficient to
inform interventions to shorten patient delay. Finding of a qualitative
research on breast cancer revealed four main themes related to the
delay in seeking medical help including: 1) attributing symptoms
to the benign conditions; 2) conditional health behavior; 3) inhibiting
emotional expression; and 4) barriers to access to health care
systems.
A meta-ethnography, which synthesized existing qualitative evi-
dence in order to gain a new understanding of help seeking behavior
in women with self-discovered breast cancer symptoms led to iden-
tification of eight repeated key concepts including: symptom detec-
tion, initial symptom interpretation, symptom monitoring, social
interaction, emotional reaction, priority of medical help, appraisal
of health services and personal-environmental factors. Symptom
interpretation was identified as the important step of the help seeking
process, which changed across the process through active monitoring
of symptoms, social interactions and emotional reactions. The per-
ceived seriousness of the situation, priority to receive medical atten-
tion, perceived inaccessibility and unacceptability of the health care
system influenced women's decision-making about using health serv-
ices. Educational programs aimed at correcting misunderstandings,
erroneous social beliefs and improving self-awareness could provide
key strategies to improve health policy which would reduce patient
delay.
Therapeutic and care issues: A correct cancer diagnosis is essen-
tial for adequate and effective treatment because every type of cancer
requires a specific treatment regimen which encompasses one or more
modalities such as surgery, and/or radiotherapy, and/or chemotherapy.
These modalities are provided in the world-class cancer treatment in
Iran. In recent decades, there was an excellent progress regarding can-
cer care and treatment in Iran. But, we need to have access to more
advanced techniques and methods including Molecular Medicine,
Nanomedicine, and non-invasive therapeutic procedures. Studies
showed that using complementary and alternative medicine among
Iranian cancer patients is unpopular. The primary goal of the thera-
peutic procedures is to cure cancer. Improving the patient's quality
of life is also an important goal which is seriously placed on the
agenda of cancer care. It can be achieved by supportive or palliative
care and psychological support.
Conclusion: The evidence suggests an increased prevalence of
cancer in Iran. Despite significant progress in the diagnosis methods
and treatment procedures of cancer in Iran, we still need a compre-
hensive strategic plan to manage all aspects of the relevant cancer
care services. According to the national upstream health documents
and strategies, it is possible to control the cancer tsunami, by focusing
on improvement the public life style.
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